Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells.
Journal
Computational and mathematical methods in medicine
ISSN: 1748-6718
Titre abrégé: Comput Math Methods Med
Pays: United States
ID NLM: 101277751
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
02
2022
revised:
02
03
2022
accepted:
12
04
2022
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
12
5
2022
Statut:
epublish
Résumé
To study the expression and prognostic value of CDK6 in stomach cancer and the function of CDK4/6 inhibitor PD-0332991 on the proliferation of stomach cancer cells. Immunohistochemistry was used to detect the expression of CDK6 in stomach cancer tissues and adjacent normal tissues and to analyze the effect of CDK6 on clinicopathological parameters of stomach cancer patients. Kaplan-Meier plotter was employed to study the relationship between CDK6 and overall survival in stomach cancer. Western blot and RT-PCR were used to detect protein and gene expression of CDK6 in different cells. The effects of CDK4/6 inhibitor PD-0332991 on apoptosis and aging of stomach cancer cells were detected by flow cytometry and (1) CDK6 was highly expressed in stomach cancer tissues and cells. (2) Abnormally elevated CDK6 expression results in shorter survival in stomach cancer patients. (3) CDK4/6 inhibitor PD-0332991 could block the proliferation of stomach cancer cells, but not stomach epithelial proliferation. PD-0332991 could inhibit the secretion of pro-GRP by MGC 823. (4) PD-0332991 could advance the development of the apoptosis and senescence of stomach cancer cells and suppressed the invasion and migration of stomach cancer cells. CDK6 expression is elevated in gastric cancer, and the CDK4/6 inhibitor PD-0332991 can remarkably promote apoptosis and senescence of stomach cancer cells and effectively inhibit the migration and invasion of stomach cancer cells.
Identifiants
pubmed: 35535229
doi: 10.1155/2022/2402567
pmc: PMC9078806
doi:
Substances chimiques
Piperazines
0
Pyridines
0
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
palbociclib
G9ZF61LE7G
Types de publication
Journal Article
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
2402567Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2022 Yu Liu et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Cancers (Basel). 2021 Nov 12;13(22):
pubmed: 34830815
Gastroenterology. 2021 Dec;161(6):1813-1829
pubmed: 34606846
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
BMJ. 2020 Nov 23;371:m3786
pubmed: 33229333
Pharmacol Ther. 2022 May;233:108028
pubmed: 34755606
Cell Death Dis. 2020 Oct 24;11(10):916
pubmed: 33099574
J Ethnopharmacol. 2020 Oct 5;260:113039
pubmed: 32497675
Ann Oncol. 2018 Jun 1;29(6):1377-1385
pubmed: 29771279
Pharmaceuticals (Basel). 2020 Nov 24;13(12):
pubmed: 33255177
Int J Cancer. 2022 Mar 15;150(6):1007-1017
pubmed: 34741530
Cancer Cell. 2020 Apr 13;37(4):514-529
pubmed: 32289274
CA Cancer J Clin. 2021 May;71(3):264-279
pubmed: 33592120
Acta Biomater. 2017 Nov;63:163-180
pubmed: 28923539
Front Immunol. 2022 Jan 14;12:799171
pubmed: 35095879
Acta Pharm Sin B. 2021 Jan;11(1):30-54
pubmed: 33532179
Trends Cancer. 2017 Jan;3(1):39-55
pubmed: 28303264
Cancer Discov. 2016 Jul;6(7):740-53
pubmed: 27217383